- Home
- BIIB vs FMS Comparison
BIIB vs FMS Comparison
Compare BIIB & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FMS
- Stock Information
- Founded
- BIIB 1978
- FMS 1996
- Country
- BIIB United States
- FMS Germany
- Employees
- BIIB N/A
- FMS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FMS Misc Health and Biotechnology Services
- Sector
- BIIB Health Care
- FMS Health Care
- Exchange
- BIIB Nasdaq
- FMS Nasdaq
- Market Cap
- BIIB 18.7B
- FMS 15.8B
- IPO Year
- BIIB 1991
- FMS 1996
- Fundamental
- Price
- BIIB $154.27
- FMS $26.84
- Analyst Decision
- BIIB Buy
- FMS Sell
- Analyst Count
- BIIB 22
- FMS 2
- Target Price
- BIIB $174.11
- FMS $30.00
- AVG Volume (30 Days)
- BIIB 1.5M
- FMS 315.2K
- Earning Date
- BIIB 10-30-2025
- FMS 11-04-2025
- Dividend Yield
- BIIB N/A
- FMS 2.12%
- EPS Growth
- BIIB N/A
- FMS 23.39
- EPS
- BIIB 10.97
- FMS 2.62
- Revenue
- BIIB $10,065,900,000.00
- FMS $22,922,038,756.00
- Revenue This Year
- BIIB $2.03
- FMS $1.83
- Revenue Next Year
- BIIB N/A
- FMS $3.27
- P/E Ratio
- BIIB $14.06
- FMS $20.17
- Revenue Growth
- BIIB 4.77
- FMS 0.53
- 52 Week Low
- BIIB $110.04
- FMS $19.26
- 52 Week High
- BIIB $179.48
- FMS $30.46
- Technical
- Relative Strength Index (RSI)
- BIIB 64.58
- FMS 51.90
- Support Level
- BIIB $138.00
- FMS $26.62
- Resistance Level
- BIIB $151.91
- FMS $27.40
- Average True Range (ATR)
- BIIB 4.62
- FMS 0.34
- MACD
- BIIB 0.21
- FMS -0.10
- Stochastic Oscillator
- BIIB 94.70
- FMS 33.65
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.